

A3

39. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is substituted or unsubstituted alkenyl.

A4

51. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is substituted or unsubstituted alkynyl.

A5

57. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is alkylcarbonyl amino.

58. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is carbonyl.

A6

63. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is substituted or unsubstituted imino.

64. [Amended] The tetracycline compound of claim 1, wherein said substituted imino is substituted with an hydroxy or alkoxy group.

65. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is NR<sup>7c</sup>(C=W')WR<sup>7a</sup>.

66. [Amended] The tetracycline compound of claim 65, wherein R<sup>7c</sup> is hydrogen, W' is oxygen and W is oxygen.

A7

70. [Amended] The tetracycline compound of claim 1, wherein R<sup>7</sup> is sulfonamido.

A8

79. [Amended] A method for treating a tetracycline responsive state in a subject, comprising administering to said subject a tetracycline compound of claim 1, such that said subject is treated.